Janux Therapeutics (NASDAQ:JANX) Upgraded at TheStreet

TheStreet upgraded shares of Janux Therapeutics (NASDAQ:JANXGet Rating) from a d+ rating to a c- rating in a report published on Tuesday, TheStreetRatingsTable reports.

Separately, William Blair started coverage on Janux Therapeutics in a research note on Monday, November 14th. They issued an outperform rating on the stock.

Janux Therapeutics Trading Down 2.6 %

NASDAQ:JANX opened at $14.00 on Tuesday. The firm has a market capitalization of $583.24 million, a price-to-earnings ratio of -9.59 and a beta of 1.33. Janux Therapeutics has a 1-year low of $9.39 and a 1-year high of $22.61. The business’s fifty day moving average price is $15.04 and its 200 day moving average price is $13.31.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of JANX. Amalgamated Bank purchased a new position in Janux Therapeutics in the first quarter valued at about $28,000. Parkwood LLC boosted its stake in shares of Janux Therapeutics by 19.4% during the 2nd quarter. Parkwood LLC now owns 33,750 shares of the company’s stock worth $34,000 after acquiring an additional 5,492 shares in the last quarter. BNP Paribas Arbitrage SNC bought a new stake in shares of Janux Therapeutics during the 3rd quarter worth about $103,000. American International Group Inc. boosted its stake in shares of Janux Therapeutics by 25.3% during the 1st quarter. American International Group Inc. now owns 8,813 shares of the company’s stock worth $126,000 after acquiring an additional 1,782 shares in the last quarter. Finally, MetLife Investment Management LLC boosted its stake in shares of Janux Therapeutics by 100.2% during the 1st quarter. MetLife Investment Management LLC now owns 10,614 shares of the company’s stock worth $152,000 after acquiring an additional 5,312 shares in the last quarter. Hedge funds and other institutional investors own 69.40% of the company’s stock.

Janux Therapeutics Company Profile

(Get Rating)

Janux Therapeutics, Inc, a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2.

Read More

Receive News & Ratings for Janux Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Janux Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.